CYP2C19基因多态性对伏立康唑不良反应发生率的影响  

Effect of CYP2C19 gene polymorphism on incidence of adverse drug reactions in Voriconazole

作　　者：李艺 张蕾[2] 冯晓俊 汪亚南 沈爱宗 刘圣[1,2] LI Yi;ZHANG Lei;FENG Xiaojun;WANG Ya′nan;SHEN Aizong;LIU Sheng(Graduate School, Anhui University of Chinese Medicine, Anhui Province, Hefei 230012, China;Department of Pharmacy, the First Affiliated Hospital of USTC (Anhui Provincial Hospital), Anhui Province, Hefei 230001, China)

机构地区：[1]安徽中医药大学研究生部,安徽合肥230012 [2]中国科学技术大学附属第一医院(安徽省立医院)药剂科,安徽合肥230001

出　　处：《中国医药导报》2019年第6期8-11,共4页China Medical Herald

基　　金：国家自然科学基金青年科学基金项目(81603339)

摘　　要：目的探讨与伏立康唑代谢相关的CYP2C19基因多态性与不良反应发生率的相关性,为临床个体化给药提供参考。方法选择2017年1月～2018年3月于安徽省立医院行CYP2C19基因检测的患者1935例,分析各基因型比例;通过病历查询判断是否用过伏立康唑以及有无不良反应,并分析各基因型患者使用伏立康唑后的不良反应发生率。结果 1935例患者中CYP2C19快(*1/*1)、中(*1/*2、*1/*3)和慢代谢(*2/*2、*2/*3和*3/*3)发生率分别为46.05%、41.34%和12.61%。1935例患者中仅有16例使用了伏立康唑。快(*1/*1)、中(*1/*2、*1/*3)、慢(*2/*2*、2/*3)代谢型患者发生不良反应的概率分别为20%、45%。结论 CYP2C19基因多态性与伏立康唑不良反应发生率存在相关性,这对患者的个体化用药具有重要指导意义。Objective To investigate the correlation between CYP2C19 gene polymorphism associated with Voriconazole metabolism and the incidence of adverse reactions, so as to provide reference for clinical individualized administration. Methods A total of 1935 patients with CYP2C19 gene test in Anhui Provincial Hospital from January 2017 to March 2018 were selected, and the proportion of genotypes was analyzed;whether or not Voriconazole was used and whether there were adverse reactions were judged by medical record inquiry, and the incidence of adverse reactions after using Voriconazole in patients with different genotypes was analyzed. Results The incidence of CYP2C19 fast (^*1/^*1), medium (^*1/^*2,^*1/^*3) and slow metabolism (^*2/^*2,^*2/^*3 and ^*3/^*3) in 1935 patients were 46.05%, 41.34% and 12.61%, respectively. Voriconazole was used in only 16 of 1935 patients. The rates of adverse reactions in fast (^*1/^*1), moderate (^*1/^*2,^*1/^*3), slow(^*2/^*2,^*2/^*3) metabolic patients were 20% and 45% respectively. Conclusion CYP2C19 gene polymorphism is correlated with the incidence of adverse drug reactions of Voriconazole, which has important guiding significance for individualized drug use in patients.

关 键 词：CYP2C19 伏立康唑 基因多态性 不良反应 

分 类 号：R969[医药卫生—药理学]